

Clinical criteria updates for specialty pharmacy

Published: Jul 1, 2021 - **Products & Programs** / Pharmacy

The following clinical criteria documents were endorsed at the May 21, 2021 Clinical Criteria meeting. Visit our [website](#) to access the clinical criteria information.

New clinical criteria effective June 5, 2021

The criteria below is new.

- ING-CC-0199: Empaveli (pegcetacoplan)

Revised clinical criteria effective June 21, 2021

The following criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0032: Botulinum Toxin
- ING-CC-0062: Tumor Necrosis Factor Antagonists
- ING-CC-0064: Interleukin-1 Inhibitors
- ING-CC-0066: Monoclonal Antibodies to Interleukin-6
- ING-CC-0098: Doxorubicin Hydrochloride Liposome
- ING-CC-0099: Abraxane (paclitaxel, protein bound)
- ING-CC-0107: Bevacizumab agents (Avastin, Mvasi)
- ING-CC-0111: Nplate (romiplostim)
- ING-CC-0120: Kyprolis (carfilzomib)
- ING-CC-0124: Keytruda (pembrolizumab)
- ING-CC-0127: Darzalex (daratumumab)
- ING-CC-0128: Tecentriq (atezolizumab)
- ING-CC-0142: Somatuline Depot (lanreotide)
- ING-CC-0150: Kymriah (tisagenlecleucel)
- ING-CC-0151: Yescarta (axicabtagene ciloleucel)
- ING-CC-0160: Vyepi (eptinezumab-jjmr)
- ING-CC-0161: Sarclisa (isatuximab-irfc)

- ING-CC-0163: Durysta (bimatoprost implant)
- ING-CC-0165: Trodelvy (sacituzumab govitecan)

Revised clinical criteria effective June 21, 2021

(The following criteria were reviewed and may have word changes or clarifications, but had no significant changes to the policy position or criteria.)

- ING-CC-0002: Colony Stimulating Factor Agents
- ING-CC-0045: Mecasermin (Increlex®)
- ING-CC-0057: Krystexxa (pegloticase)
- ING-CC-0061: GnRH Analogs for the Treatment of Non-Oncologic Indications
- ING-CC-0068: Growth hormone
- ING-CC-0069: Egrifta (tesamorelin)
- ING-CC-0087: Gamifant (emapalumab-lzsg)
- ING-CC-0092: Brentuximab Vedotin (Adcetris)
- ING-CC-0105: Vectibix (panitumumab)
- ING-CC-0106: Erbitux (cetuximab)
- ING-CC-0116: Bendamustine agents
- ING-CC-0134: Provenge (sipuleucel-T)
- ING-CC-0143: Polivy (polatuzumab vedotin-piiq)
- ING-CC-0153: Adakveo (crizanlizumab)
- ING-CC-0162: Tepezza (teprotumumab-trbw)
- ING-CC-0166: Trastuzumab Agents
- ING-CC-0171: Zepzelca (lurbinectedin)
- ING-CC-0175: Proleukin (aldesleukin)
- ING-CC-0178: Synribo (omacetaxine mepesuccinate)
- ING-CC-0183: Sogroya (somapacitan-beco)
- ING-CC-0192: Cosela (trilaciclib)
- ING-CC-0195: Abecma (idecabtagene vicleucel)

Revised clinical criteria effective July 1, 2021

The following criteria were revised to expand medical necessity indications or criteria.

- ING-CC-0125: Opdivo (nivolumab)

Revised clinical criteria effective July 1, 2021

(The following criteria were updated with new procedure and/or diagnosis codes.)

- ING-CC-0061: GnRH Analogs for the Treatment of Non-Oncologic Indications
- ING-CC-0075: Rituximab Agents for Non-Oncology Indications
- ING-CC-0167: Rituximab Agents for Oncologic Indications Step Therapy
- ING-CC-0184: Danyelza (naxitamab-gqgk)
- ING-CC-0185: Oxlumo (lumasiran)
- ING-CC-0186: Margenza (margetuximab-cmkb)
- ING-CC-0187: Breyanzi (lisocabtagene maraleucel)
- ING-CC-0189: Amondys 45 (casimersen)
- ING-CC-0191: Pepaxto (melphalan flufenamide; melflufen)
- ING-CC-0192: Cosela (trilaciclib)
- ING-CC-0193: Evkeeza (evinacumab)
- ING-CC-0194: Cabenuva (cabotegravir extended-release; rilpivirine extended-release) Injection

New clinical criteria effective October 1, 2021

(The criteria below is new and may result in services previously covered now being considered either not medically necessary and/or investigational)

- ING-CC-0196: Zynlonta (loncastuximab tesirine-lpyl)
- ING-CC-0197: Jemperli (dostarlimab)
- ING-CC-0198: Relizorb (immobilized lipase) cartridge

Revised clinical criteria effective October 1, 2021

(The following criteria listed below might result in services that were previously covered now being considered either not medically necessary and/or investigational.)

- ING-CC-0032: Botulinum Toxin
- ING-CC-0062: Tumor Necrosis Factor Antagonists
- ING-CC-0066: Monoclonal Antibodies to Interleukin-6
- ING-CC-0107: Bevacizumab agents (Avastin, Mvasi)
- ING-CC-0111: Nplate (romiplostim)
- ING-CC-0114: Jevtana (cabazitaxel)
- ING-CC-0124: Keytruda (pembrolizumab)

- ING-CC-0128: Tecentriq (atezolizumab)
- ING-CC-0137: Cablivi (caplacizumab-yhdp)
- ING-CC-0145: Libtayo (cemiplimab-rwlc)
- ING-CC-0160: Vyepiti (eptinezumab-jjmr)

1220-0721-PN-NE

URL: <https://providernews.anthem.com/maine/article/clinical-criteria-updates-for-specialty-pharmacy-59>

Featured In:

July 2021 Connecticut Provider News, July 2021 Maine Provider News, July 2021 New Hampshire Provider News

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by CompCare or WCIC; CompCare Health Services Insurance Corporation (CompCare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.
